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Background: Diarrhea caused by Enterobacteriaceae such as Shigella species and Escherichia coli (E. coli) is endemic 
throughout the world, and is one of the most important causes of global childhood mortality and morbidity. There is a 
range of antibiotics that can be used for treatment among them quinolones. However, there is emerging increase in 
microbial resistance to quinolones use, with E. coli and Shigellae among the species of bacteria commonly associated 
with quinolone resistance.  
Objective: To investigate the prevalence of quinolone resistance genes in Shigellae and E. coli from patients 
presenting with diarrhea in Machakos District Hospital. 
Methods: Bacteria isolates were identified to species level by biochemical methods and serology and thereafter tested 
for 12 different antibiotics including quinolones, cephalosporins and aminoglycosides. Those resistant to quinolones 
with a zone diameter of ≤20 mm were tested for the presence of quinolone resistance genes using PCR. The gyrA 
resistance genes were further analyzed by sequencing to determine mutations within the quinolone resistance 
regions. 
Results: There were different E. coli pathotypes and Shigellae spp.  They resisted more than four antibiotics: 
Ciprofloxacin (4%), (Chloramphenical (28%), Cotrimoxazole (78%), Co-amoxilav (70%) Erythromycin (98%) 
Cefotoxime (18%) and Tetracycline (56%). Mutations responsible for fluoroquinolone resistance in the gyrA, gyrB, 
parC, and parE genes of E. coli and Shigella spp were: gyrA (17/30, 36%) gyrB (7/30, 23.3%) topoisomerase (parC 
3/30, 10%) parE (3/30, 10%).   
Discussion: There is an increase in fluoroquinolone resistance in Shigellae and E.coli which points to a major 
challenge in current treatment strategies. In addition, detection of high resistance found to commonly used antibiotics 
should serve as a warning call for close surveillance and understanding of the epidemiology of the resistance.  
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1. Introduction 
Shigellosis caused by Shigella species is endemic 
throughout the world, and is one of the most important 
causes of global childhood mortality and morbidity. 
Globally, every year there are about 165 million cases of 
Shigella infection and 1.1 million Shigella-related deaths 
[Kotloff wt al., 1999]. Shigella is transmitted efficiently 
in low-dose via fecal-oral route in areas, with poor 
hygienic conditions, and limited access to clean and 
potable water [Weissman et al, 1975]. Of four Shigella 
species, shigellosis is predominantly caused by S. 
flexneri in the developing world especially in Asia, 
whereas S. sonnei is the predominant causative agent of 
this disease in developed as well as industrialized 
countries [Kotloff et al, 1999]. A recent multicenter 
study of the epidemiology and microbiology of 
shigellosis in Asia revealed that the incidence of this 
disease might even exceed previous estimations, as 
Shigella DNA could also be detected in up to one-third of 
culture-negative specimens [von Seidlein et al, 2006]. 
Antimicrobial therapy is effective for the treatment of 
shigellosis. Increased resistance to commonly used 
antibiotics including ampicillin, streptomycin, 
sulfamethoxazole-trimethoprim, nalidixic acid and 
tetracycline among Shigella poses a major therapeutic 
challenge to control this disease [Dutta et al, 2002]. One 
of the reasons for emergence of multi-drug resistant 
Shigella spp. is the unique capability of the pathogen to 
acquire resistance factors (transmissible genes) from 
the environment or from other bacteria [Sack et al, 
1997]. Besides, indiscriminate use of antibiotics for the 
treatment of human infection and in animal 
husbandries in endemic areas triggers the increase of 
resistance to newer antibiotics [Barbosa et al, 2000]. 
Ciprofloxacin, a third generation fluoroquinolone, has 
been used successfully for the treatment of infectious 
diseases including shigellosis. Following a successful 
clinical trial, ciprofloxacin has been recommended for 
the treatment of both childhood and adult shigellosis 
caused by multiple antibiotic resistant Shigella spp. in 
Bangladesh [Salam et al, 1998]. However, this antibiotic 
is no longer effective for the treatment of shigellosis in 
south Asian region including Bangladesh because of the 
emergence of fluoroquinolone resistant S. dysenteriae 
type 1 and their (same clone) dissemination across the 
countries [Talukder et al, 2004; Talukder et al, 2006]. 
Quinolone resistance emerges due to i) point mutations 
that result in amino acid substitution in chromosomal 
genes for DNA gyrase and topoisomerase IV, the targets 
of quinolone action and ii) changes in expression of 
efflux pumps and outer membrane permeability that 
control the accumulation of these agents inside the 
bacterial cell [Drlica et al, 1997; Poole., 2000]. In 
addition, a novel mechanism of plasmid-mediated 
quinolone resistance has recently been reported, and 
this involves DNA gyrase protection by a protein from 
the pentapeptide repeat family called Qnr [Wang et al, 
2004; Tran et al, 2005]. In Gram-negative organisms, 
the primary target of fluoroquinolones is the enzyme 
DNA gyrase, which is essential for DNA synthesis [Tran 
et al, 2005]. DNA gyrase consists of two A and two B 
subunits, encoded by the GyrA and GyrB genes, 
respectively. Most mutations have been shown to reside 
in a small region near the start of the GyrA gene, termed 
as quinolone resistance-determining region (QRDR), 
although mutations have also been reported in gyrB 
[Piddock., 1995]. Genes encoding topoisomerase IV 
consists of two subunits parC and parE which have also 
been shown to be inhibited by fluoroquinolones. In 
Gram-negative bacteria, topoisomerase IV has been 
considered as the secondary target to flouroquinolones 
and alteration in parC is involved in the mechanism of 
resistance [Everett et al, 1996]. The level of MICs of 
fluoroquinolones has been shown to correlate with the 
type and number of amino acid substitution of the 
target genes within the QRDR [Truong et al, 1997; 
Komp Lindgren et al, 2003; Turner et al, 2006; Morgan-
Linnell et al, 2007]. In our previous study, possible 
mechanisms of fluoroquinolone resistance were 
analyzed in clinical strains of S. dysenteriae type 1 
isolated from India, Nepal and Bangladesh [Talukder et 
al, 2006]. 
It has also been reported that fluoroquinolone 
resistance is often the result of a combination of target 
site mutations and enhanced expression of genes 
encoding efflux pumps in resistant bacteria [Kim et al, 
2008]. In this study, we report the first isolation of 
fluoroquinolone resistant S. flexneri, S. boydii and S. 
sonnei in Bangladesh. In addition, the mechanism of 
chromosome mediated fluoroquinolone resistance in S. 
flexneri strains, which results from the combination of 
target site mutation and energy dependent active 
pumps involvement has been determined. 
2. Methodology 
2.1 Study design and Study population 
This was a cross sectional study carried out from 2010 
to 2013 in Machakos District Hospital. 
The study targeted patient from three months and 
above who presented to the hospital for treatment due 
to diarrhea infection. Eligibility for inclusion into the 
study were patients with three or more episodes of 
loose, watery, mucoid or bloody diarrhea in a day; those 
who had given consent to participate in the study and 
those who had not taken any antibiotic before visiting 
the hospital.  
2.2 Patient recruitment 
Based on the studies done in Kenya (Karuiki et al, 
2002), and using Kaper formula (Kapar et al, 1980), we 
arrived at a sample size of 300 patients. Before 
enrollment, the details of study were explained to the 
patient by the study nurse and allowed to ask questions 
for clarifications. Every third patient was recruited 
voluntarily into the study after signing of informed 
consent. 
2.3 Sample collection 
After the patient or guardian had been thoroughly 
briefed about the study and given signed consent to 
participate, the patient was given a sterile stool cup to 
collect a single stool sample. In case of a minor, the 
guardian or parent gave the consent. Care was taken 
during stool collection to avoid contamination with 
urine, soil or water. Part of the collected stool was 
transferred into Carry Blair transport medium and 
shipped to Kenya Medical Research Institute 
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Microbiology laboratory for processing and 
identification. 
2.4 Bacterial identification 
Bacteria isolates were identified to species level by 
biochemical methods and serology (Kariuki et al, 2002)  
and thereafter tested for susceptibility to 12 different 
antibiotics including quinolones, cephalosporins and 
aminoglycosides by the agar diffusion method using 
Kirby Buer method. 
2.5 Antimicrobial susceptibility testing: 
Antimicrobial susceptibility testing (disc diffusion and 
Minimum inhibitory concentration{MIC}) were carried 
out based on Clinical and Laboratory Standards 
Institute (CLSI,2012) recommendations using the 
following discs; (Amp; 10 µg), sulphamethoxazole-
trimethoprim (Sxt; 25 µg), mecillinam (Mel; 25 µg), 
nalidixic acid (Na; 30 µg), ciprofloxacin (Cip; 5 µg), 
norfloxacin (Nor; 10 µg), ofloxacin (Of; 5 µg), 
azithromycin (Azm; 15 µg), and ceftriaxone (Cro; 30 µg) 
[CLSI, 2012]. The minimum inhibitory concentrations 
(MICs) of nalidixic acid, ciprofloxacin, norfloxacin, 
ofloxacin, azithromycin, and ceftriaxone were 
determined by the E-test (AB Biodisk, Solna, Sweden) 
using a 0.5 McFarland standard. Those that were 
resistant to quinolones were tested for the presence of 
the gyrase and topoisomerase resistance genes using 
PCR for detection of GyrA, GyrB, PerC and perE. 
Thereafter conjugation and sequencing was carried out 
to determine resistance factors mutations in the 
quinolone resistance regions respectively. 
2.6 Amplification of GyrA, GyrB, perE, perC:  
Multiplex PCR of some representative strains was 
performed to detect the GyrA, GyrB, qnrS and aac(6¢)-
Ib-cr according to the procedure described earlier [kim 
et al, 2008]. The primer sequences are: 
5′-AGAGGATTTCTCACGCCAGGA-3′ and  
5′-GGCTGGCCGATTATGATTGGT-3′ for qnrA;  
5′-GGCTGGCCGATTATGATTGGT-3′ and  
5′-CGCGTGCGATGAGATAACC-3′ for GyrB;  
5′-TGCCACTTTGATGTCGCAGAT-3′ and  
5′-CGCACGGAACTCTATACCGTAG-3′ for perE; and  
5′-ATCTCATATCGTCGAGTGGTGG-3′ and  
5′-CGCTTTCTCGTAGCATCGGAT-3′ for perC. 
2.7 Plasmid profile analysis 
Plasmid DNA was prepared by the alkaline lysis method 
of Kado and Liu, with some modifications [Talukder et 
al, 2003]. The molecular weight of the unknown 
plasmid DNA was assessed by comparing the mobility of 
the plasmids of known molecular mass as described 
previously [Talukder et al, 2004]. 
2.8 Determination of resistance factor 
A conjugation experiment between the multidrug-
resistant (AmpR SxtR CipR) donors, S. flexneri serotype 
2a K9482and K9563 strains, and the recipient, E. coli K-
12 (Lac− F−), was carried out by a procedure described 
elsewhere [Munshi et al, 1987]. Transconjugant 
colonies were selected on MacConkey agar plates 
containing Amp (50 mg/L). Plasmid analysis and 
antimicrobial susceptibility testing of the 
transconjugants were carried out to determine the 
transfer of plasmids with antibiotic resistance. 
2.9 Pulsed Field Gel Electrophoresis (PFGE) 
Genomic DNA of various strains of E. coli, Shigella spp 
and Salmonella spp were prepared in agarose plugs as 
described by Kariuki et al. (2000: 2001) from an 
overnight culture in Luria batani broth. For complete 
digestion of DNA, the XbaI (Life Technologies, Paisley, 
UK) enzymes were added according to the 
manufacturer’s instructions. PFGE of agarose plug 
inserts was performed in the contour clamped 
homogenous electric field CHEF-DRIII (Bio-Rad 
Laboratories, Hercules, CA, USA) on a horizontal 
agarose 1% gel for 22 h at 120V, pulse time of 1 to 40 
sec at 14oC. A DNA size standard (lambda ladder, Bio-
Rad) consisting of (c. 22 fragments) of increasing size 
from 48kb -1000kb were used as the DNA size standard 
makers. The gels were stained with 0.05% ethidium 
bromide and observed on a gel Doc 2000 (Bio-Rad). 
Restriction endonuclease digest pattern of all XbaI 
digest genomic DNA were compared and similarities 
and differences scored basing on Tenovar’s method 
(Tenovar et al, 1997). Using the Dice coefficient method 
and clustered by the unweighted pair group arithmetic 
averaging method (molecular Fingerprinting program 
version 1.4.1, Bio-Rad) that puts the isolates into PFGE 
clonal groups (Kariuki et al, 2002; Kariuki et al, 2004). 
Those isolates showing indistinguishable PFGE banding 
were taken to be part of the outbreak while isolates 
showing 2-3 band difference in PFGE patterns were said 
to be closely related and possibly part of the cause of 
disease. Those with 4-6 band differences were assumed 
possibly related, and, those with more than 6 band 
differences were deemed different (Tenovar et al, 
1997). 
2.10 DNA sequence analysis:  
Chromosomal DNA from selected representative strains 
was prepared and purified by procedures described 
previously [Tenover et al, 1995]. Polymerase chain 
reaction (PCR) for gyrA, gyrB, parC were performed 
according to the procedures described earlier [Jacoby et 
al, 2003; Jacoby et al, 2003; Rahman et al, 1994; Wang 
et al, 2001]. PCR amplicons were purified with the GFX™ 
PCR DNA and gel band purification kit (Amersham 
Pharmacia, USA). Sequencing of the amplicons was 
performed using the dideoxy-nucleotide chain 
termination method with the ABI PRISM® BigDye 
Terminator Cycle Sequencing Reaction kit (Perkin-
Elmer Applied Biosystems, Foster City, California) on an 
automated sequencer (ABI PRISM™ 310). The 
chromatogram sequencing files were inspected using 
Chromas 2.23 (Technelysium, Queensland, Australia), 
and contigs were prepared using SeqMan II (DNASTAR, 
Madison, WI). Nucleotide and protein sequence 
similarity searches were performed using the National 
Center for Biotechnology Information (NCBI, National 
Institutes of Health, Bethesda, MD) BLAST (Basic Local 
Alignment Search Tool) server on GenBank database, 
release 138.0 [Altschul et al, 1990]. Multiple sequence 
alignments were developed using CLUSTALX 1.81 
[Thompson et al, 1997]. Sequences were manually 
edited in the GeneDoc version 2.6.002 alignment editor. 
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2.11 Ethical considerations 
Ethical approval for the study was granted by the Kenya 
Medical Research Institute - Ethical Review Committee 
(Ref. No.: SSC 989). 
3.  Results  
Drug susceptibility profile of E. coli and Shigellae 
isolates  
The study recruited and analyzed samples from 300 
patients (male and female) who presented with 
diarrhea for treatment. The patient ages ranged from 
three months and above. The samples analyzed 
included Shigellae 67/300(22.3%), E. coli 500 (52%), 
Klebsiella pneumoniae 37(12.3%), Salmonella spp 
1/300(0.3%), Proteus spp 1/300(0.3%) and Serratia 
marcescens 1/300(0.3%). They were resistant to more 
than four antibiotics including Ciprofloxacin (4%), 
Nalidixic acid (12%), Erythromycin (98%), co-
amoxilav(70%) , Ceftriaxone(6%), Cefotoxime(17%), 
Ampicilin (80%), Co-tromoxazole (78%),  and 
Chloramphenicol (28%) (Figure 1, Table 1). 
Considering quinolones alone; different bacteria varied 
slightly in their resistance: E. coli (40/500); 
Shigellae(6/67); K. pneumonia(3/37); Salmonella(0/1); 
Proteus(0/1) and S. marcescens(1/1). 
Minimum inhibitory concentrations (MIC) for 
bacteria isolates 
The MICs for both Shigellae and pathogenic E. coli 
isolates indicated  raised MICs especially for Quinolones 
(0.16µg/ml)  compared to the normal range (0.002- 4) 
implying a possibility for limited antimicrobial therapy 
(Table 2). 
        Figure 1. Drug susceptibility profile of E. coli and Shigellae isolates 
 
     Table 1. Antimicrobial resistance phenotypes 
Antibiotic Resistance Patterns  Resistance Frequency (%) 
AMP  19% 
AMP/SXT 28% 
AMP/SXT/ TE 42% 
AMP/SXT//NA/CIP  14% 
AMP/SXT/E  33% 
AMP/SXT/CAZ/CN  12% 
AMP/SXT/ TET/C/NA  16% 
AMP/SXT/TET/NA/CAZ/AMC/CXM  2% 
Key: AMC: Augumentin, SXT: Sulfamethoxazole, CN: Canamycin, CXM: Cefuroxime, CIP: Ciprofloxacin, AMP: Ampicilin, 
C: Chloramphenicol, NA: Nalidixic acid, TE: Tetracyclin, CAZ: Cefetazidine, E:Erythromycin 
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   Table 2: Minimum Inhibitory Concentration for E. coli and Shigellae isolates. 
 E. coli  Shigellae 
Drug 
MIC 50 
(µg/mL) 
MIC 90 
(µg/mL) 
Ranges 
(µg/mL) 
 MIC 50 
(µg/mL) 
MIC 90 
(µg/mL) 
Ranges 
(µg/mL) 
Co-trimoxazole 36 38 0.002 - 32  >2/38 >4/38 0.002 - 32 
Amikacin 16 16 0.16 - 256  >16 >16 0.16 - 256 
Gentamicin 4 6 0.16 - 256  4 8 0.16 - 256 
Chloramphenicol 24 64 0.16 - 256  >16 64 0.16 - 256 
Ciprofloxacin 0.08 0.16 0.002 - 4  0.16 0.4 0.002 - 4 
Cefuroxime 16 16 0.16 - 256  >16 >16 0.16 - 256 
Cefotoxime 32 32 0.16 - 32  > 8 32 0.16 - 32 
Ceftazidime 32 32 0.16 - 256  8 32 0.16 - 256 
Cefpodoxime 16 16 0.16 - 256  8 16 0.16 - 256 
Tetracycline 8 24 1.5 - 256  32 64 1.5 - 256 
 
Gyrase A, B and Topoisomerase detection 
Detection of resistance genes and determination of 
mutations that were responsible for fluoroquinolone 
resistance in the gyrA, gyrB, parC, and parE genes of E. 
coli and Shigellae spp were investigated by mPCR using 
primers  that were highly specific (Figure 2) and 
sequencing (Table 3) respectively.  From the isolates 
tested, 30/300(10%) were positive for the above genes. 
The genes were distributed as follows: gyrA (17/30, 
36%) gyrB (7/30, 23.3%) topoisomerase (parC 3/30, 
10%) parE 3/30, 10%). Out of the 17/30 gyrA genes 9 
were extracted from ETEC, 6 from Shigellae, and 2 from 
atypical E.coli. GyrB resistant genes were distributed as 
follows: 2 from Enterotoxigenic E. coli (ETEC), 3 
Shigellae, and 2 from atypical Enteropathogenic E. coli 
(EPEC). Topoismerase genes (parC and parE) were only 
recovered from Shigellae. The genes were isolated from 
children below age of five years and those above 40 
years. 
Test for invasiveness 
All 67 Shigella strains harbored the invasive plasmid 
and had the ability to amplify for ipaH gene. 
 Plasmid profile analysis  
Analysis of plasmid DNA revealed that out of the 33 
multidrug resistant strains tested  (33/33, 100%) 
contained multiple plasmids whose sizes ranged from 
1.8 to 35 kb, forming a number of unique banding 
patterns as shown in (Figure 3) All strains carried more 
than two plasmids. They all transferred their resistance 
phenotypes to four antibiotics (Ampicillin, Nalidixic 
acid, cotrimoxazole and chloramphenicol) to the 
recipient E. coli K12 100% sensitive for the above 
antibiotics. After conjugation, the transconjugant E. coli 
K12 was 100% resistant to Ampicillin, Nalidixic acid, 
cotrimoxazole and chloramphenicol. This confirmed the 
fact that resistance observed to a range of antibiotics 
was plasmid mediated. 
  Figure 2. PCR products of the GyrA, B, par C and par E quinolone resistance genes in E. coli and Shigella spp 
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Figure 3: Plasmid profiles of multi drug resistant E. coli and Shigellae spp 
 
Figure 4. PFGE patterns of Xba1 digest Shigella spp and E. coli isolated from patients 
 Analysis of PFGE profile 
PFGE analysis of Xba1-digested chromosomal DNAs of 
the atypical E. coli, S. flexneri S. dysenteriae, and S. boydii 
strains yielded 16 to 19 reproducible DNA fragments 
ranging in size from 20 to more than 640 kb (Figure 4).   
Shigellae isolates 38/67 (56.7%), 25/67 (37.3%) and 
4/67(6%) had 2,3 or 4 band difference respectively, 
while E. coli (350/500(70%) had undistinguishable 
bands (2-3 bands). 
Mutations in quinolone resistance determining 
regions 
Sequencing was carried out on 30 randomly selected 
isolates that were resistant to quinolones. All sequences 
of the quinolone resistance-determining region of the 
gyrA gene (17/30, 56.7%) in the isolates which showed 
decreased susceptibilities or complete resistance had a 
single or double mutation at either the Ser-83 or the 
Asp-87 codon. There was no mutations observed in the 
gyrB (7/30, 23.3%), par C 3/30, 10%) or par E (3/30, 
10%) genes (Figure 5, Table 3).  
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Sequence alignment for quinolone resistance 
regions 
The sequences were aligned and analyzed using 
MRbayes software and phylogenetic tree drawn using 
the fig tree for determination of relatedness of the 
isolates in terms of GyrA gene mutations (Figure 5). 
The tree yielded five clusters. Isolates from this study 
clustered successfully with those from the gene bank 
bearing the GyrA resistance genes. The conversions and 
comparisons in base alignment was analysed by ESS 
using tracer software and black colour outcome 
indicated a success in the conversions from the 17/30 
(56.7%) isolates and a dendrogram drawn by neighbour 
joining (Figure 5). Gyr7 was the only different isolate 
(1/30, 3.3%). It was routed out of the other sequences 
implying that it was different. The other gyrA resistant 
isolates (16/17, 94.1%) clustered 100% with sequences 
of quinolone resitance genes obtained from the gene 
bank.  This implied that GyrA reistance genes were 
resisponsible for observed resistance in ciprofloxacin, 
Nalidixic acid and Norfloxacin. 
The single amino acid switch was thought to be the 
cause for resistance to the quinolones (Table 3). 
Mutations were detected at amino acid 83 and 87. 
Nucleotide sequences accession number 
The nucleotide sequences reported in this paper were 
submitted in GenBank using the National Center for 
Biotechnology Information (NCBI, Bethesda, MD Sequin, 
version 5.26) under accession numbers - JX908762, 
JX908763, and JX908764. 
 
   Figure 5. Consensus tree of Gyrase A genes and its nearest neighbours 
 
     Table 3. Fluoroquinolone resistance and amino acids substitution in bacteria isolates  
Strain 
MIC (μ/ml)  Amino acid switch 
CIP NOR NA  GyrA 
MKS S. dysenteriae 0.5 0.03 1  Ser83 Ser 87 
MKS EPEC 0.09 0.19 >256  Ser83-Leu Asp87 
MKS ETEC 6 12 >256  Ser83-Leu Asp87 - Gly 
MKS ETEC 200 250 >256  Ser83-Leu Asp87 - Gly 
MKS S. flexneri 0.012 0.023 1.25  Ser83 Ser87 
MKS S. boydii 64 250 >256  Ser83-Leu Asp87 - Asn 
MKS S. sonnei 0.16 0.014 >256  Ser83-Leu Ser87 
      Key: MKS denotes Machakos 
  
 GyrA_3_Contig
 Gyr_A_10_Contig2
 GyrA_9_Contig
 GyrA_16_Contig
 Gyr_11_Contig
 GyrA_1_Contig
 GyrA_7_Contig
 gi|15963416|dbj|AB072397.1|_Pseudomonas_putida
 gi|16555884|dbj|AB072701.2|_Salmonella_enterica
 gi|16555886|dbj|AB072702.2|_Salmonella_paratyphi
 GyrA_6_Contig1
 gi|15787865|dbj|AB071987.1|_Salmonella_enterica
 gi|16041049|dbj|AB072700.1|_Salmonella_paratyphi
 GyrA_5_Contig
 gi|15721888|dbj|AB071871.1|_Salmonella_paratyphi_gyrA
 GyrA_2_contig
100
99
68
73
59
100
65
98
88
52
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4. Discussion 
From the study, different E. coli pathotypes and 
Shigellae spp  were detected among them 
Enteropathogenic E. coli (EPEC), Enteroinvassive E. coli 
(EIEC) Enteroaggregative E. coli (EAEC) and colonizing 
necrotizing factors (CNF) S. dysenteriae, S. flexineri, S. 
sonnei, S. boydii respectively  representing 42.6% and 
23% of bacteria isolated respectively. The isolates from 
the current study exhibited resistance to 
floroquinolones ranging from 4 to 12% (Figure 1) 
contrally to other studies done in Kenya that indicated 
no resistance to Ciprofloxacin (Kariuki et al, 2004). 
Resistance reported in this study was higher (upto 
12%) than what has been reported before. 
Fluoroquinolones have become the first-line drugs for 
the treatment of bacillary dysentery and typhoid fever 
(Pazhani et al, 2011; Felmingham et al, 2007). S. 
dysenteriae, S. flexineri, S.boydii, S. sonnei, and E. coli 
strains that exhibit decreased susceptibilities or 
complete resistance to fluoroquinolones and other 
antibiotics have been reported elsewhere (Juma, et al, 
2016; Mendez et al, 2009; Menendez et al, 2004; Hirose 
et al, 2001).  
Several clinical treatment failures after the 
administration of ciprofloxacin and other 
fluoroquinolones to patients with dysentery and 
typhoid fever due to strains with decreased 
susceptibilities and /or resistance to fluoroquinolones 
have also been reported (Martinez-Martinez et al, 2003; 
Olsen et al, 2001). The emergence and spread of these 
organisms have been reported in developing countries 
including Kenya and Nigeria (Kariuki et al, 2004; Aibinu 
et al, 2007). There is evidence that the incidence of 
strains that are resistant to Nalidixic acid and that 
exhibit decreased susceptibilities to the most recent 
fluoroquinolones used for the treatment of shigellosis is 
increasing (Strahilevitz et al, 2009; Tran et al, 2002). 
 In most E. coli and Shigellae strains in the current study, 
the detected fluoroquinolone resistance was attributed 
to mutations due to single amino acid switch (Table 3) 
in the genes encoding DNA gyrase (GyrA) while studies 
in other regions indicate mutations in GyrA, B and DNA 
topoisomerase IV (ParC and ParE) (Kato et al, 1990). In 
this study, no mutation was detected in Gyr B, 
topoisomerase IV C and E. The resistance was found to 
be transferable  and transconjugant analysis revealed 
transfer of resistance traits from multidrug resistant E. 
coli and Shigella spp to recipient E. coli K12. (Figure 3). 
From the current study, 12% of the isolates were 
resistant to ciprofloxacin. This was in contrast to the 
study findings by Sinha et al, (2004) where typical 
resistant strains for ciprofloxacin were never found 
among the strains tested in their work. In the current 
study, the resistant Shigella dysenteriae, S. flexneri, S. 
boydii, S. sonnei and E. coli isolates to fluoroquinolone 
had single mutation in the gyrA gene, at either position 
83 or 87 (Table 3). This was also contrary to the results 
of Kariuki et al, 2004 findings where mutations were 
detected in GyrA, B and topoisomerase IV. This agreed 
with the PFGE pattern implying no variation in E. coli or 
Shigelae (Figure 4).  
In quinolone resistance, there are three groups 
distinguished among the strains in which resistance is 
observed in vitro on the basis of the ciprofloxacin MICs 
and gyrA mutations. The first group consisted of strains 
which were susceptible to fluoroquinolones and which 
had no mutations in the QRDR of the gyrA gene and this 
was in agreement with the work done elsewhere 
(Piddock, 1998 and 2002; Konstantinos et al, 2008). The 
second group consisted of strains which exhibited 
slightly reduced susceptibilities to fluoroquinolones by 
MICs (or intermediate by disc diffusion and which had 
only a single mutation in the QRDR of the gyrA gene. 
The third group consisted of strains which were 
resistant to fluoroquinolones with a single mutation in 
the QRDR of the gyrA gene. These findings indicate that 
gyrA mutations are of principal importance for the 
fluoroquinolone resistance of Shigella spp and E. coli.   
Alterations at position 83 or 87 of the GyrA amino acid 
sequence have been described for Salmonella strains 
(Pazhani et al, 2011; Kariuki et al, 2004; Piddock et al, 
2002; D’Ignazio et al, 2005). Double mutations at both 
positions 83 and 87 of the GyrA amino acid sequence 
were also reported in clinical isolates of serovar 
Schwarzengrund, which caused nosocomial infections 
in the United States and which exhibited ciprofloxacin 
resistance (Rodas et al, 2011), a phenomenon that was 
not observed in the current study. Although strains with 
high-level fluoroquinolone resistance due to double 
mutations at codons 83 and 87 in the GyrA amino acid 
sequence were not found in clinical isolates of Shigella 
spp, and E. coli in the current study. Several cases of the 
failure of treatment for shigellosis due to strains with 
decreased susceptibilities or total resistance to 
fluoroquinolones have  been reported elsewhere 
(Ouyang-Latimer et al, 2011; Smith et al, 2010; 
Felmingham et al, 2007; Tran et al, 2002). From this 
study in comparison with the work done in the region 
(Kariuki et al, 2004), we conclude that fluoroquinolone 
resistance is increasing. This therefore possess danger 
in choice of antibiotics in the management of diarrheal 
illness due to Shigellae and E. coli. Active surveillance is 
therefore recommended in order to minimize the 
resistance. Observed resistance was attributed to single 
mutation at either position 83 or 87 of the quinolone 
resistance determining region. 
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